Investors must not rely on this information for investment decisions. No information provided on this website constitutes an offer of solicitation for the purchase or disposal of, trading or any transaction in any Daiichi Sankyo securities or products. ![]() The Expressly Downloadable Images may be used for non-commercial use, provided you also retain all copyright notices. ![]() ![]() Except for the images expressly stated to be “Downloadable” on the site (“Expressly Downloadable Images”), the further use, re-use, copying, distribution, redistribution, modification, publication, or re-posting of or to any part of this site (including the text, images, audio, and video) is strictly prohibited and nothing contained on this site should be construed as granting, by implication, estoppel, or otherwise, any licence or right to use any Daiichi Sankyo intellectual property right (including, but not limited to any patent, trademark, trade name, copyright or trade secret). You may print a single copy of the content for your own personal, non-commercial use, provided you also retain all copyright and other proprietary notices contained in the materials or as specified on the site. Daiichi Sankyo neither warrants nor represents that your use of material displayed on the site will not infringe rights of third parties. All images and text are owned by or licenced to Daiichi Sankyo and, except as provided within these Terms and Conditions, may not be downloaded, distributed, stored, reused, reposted, modified, or otherwise used without the express written permission of Daiichi Sankyo. Copyrights and TrademarksĪll content of this website, such as text, publications, newsletters, articles, opinions, minutes, notices, views, graphics, images, HTML code, multimedia clips, Java code, and the selection and arrangement of information ("materials") is protected by copyright and other intellectual property laws. The information on this site should not be relied on in providing medical advice. The content of this site is NOT INTENDED TO PROVIDE MEDICAL ADVICE, nor meant to be a substitute for advice provided by a physician or other qualified healthcare professional. By accessing and browsing the site, you accept, without limitation or qualification, the Terms and Conditions. While you are free to browse the site, your access to and use of the site is subject to the following terms and conditions (“Terms and Conditions”) and all applicable laws. 2ĭaiichi Sankyo Europe GmbH (“Daiichi Sankyo”) maintains such parts of this site that are expressly directed to an international audience except the UK, USA and Japan for information, education, and communication. ![]() The primary safety end point was the time to the first occurrence of major bleeding as defined by the International Society on Thrombosis and Haemostasis as (i) fatal bleeding and/or (ii) symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome, and/or (iii) bleeding causing a fall in haemoglobin level of 2.0 g/dL or more, or leading to transfusion of two or more units of whole blood or red cells. The primary efficacy end point was the composite of all stroke (ischemic or hemorrhagic) or systemic embolism (S/SE). 1ĭ CrCl 30–50 mL/min is one of three items for dose reduction criteria.Į Includes patients assigned to the LIXIANA ® 60 mg group, who met the dose reduction criteria and took LIXIANA ® 30 mg instead of 60 mg. 1ī Includes patients taking LIXIANA ® 60 mg and those dose-reduced to 30 mg.Ĭ Median time-in-therapeutic range (TTR): 66.9% in CrCl 30–50 mL/min, and 68.7% in CrCl > 50 mL/min, respectively. A Stratified by CrCl 30–50 mL/min (moderate dysfunction) and > 50 mL/min (mild or no dysfunction).
0 Comments
Leave a Reply. |